Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vivani Medical, Inc. - Common Stock (NQ: VANI ) 1.290 +0.030 (+2.38%) Streaming Delayed Price Updated: 3:54 PM EDT, Oct 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vivani Medical, Inc. - Common Stock Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 October 22, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia September 26, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 September 23, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant September 04, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference August 28, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results August 13, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115 July 11, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant June 13, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant May 28, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results May 13, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Present at TIDES Conference 2024 May 09, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results March 26, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Appoints Daniel Bradbury to its Board of Directors March 06, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant March 06, 2024 The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher Via MarketBeat Exposures Product Safety Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants March 01, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio February 28, 2024 From Vivani Medical, Inc. Via Business Wire Vivani Medical Provides Business Update and Reports Third Quarter Financial Results November 14, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Present at BIO Investor Forum October 16, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Present at the Boulder Peptide Symposium September 07, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10 September 05, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Reports Second Quarter Financial Results and Provides Business Update August 14, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System July 11, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest June 14, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Reports First Quarter Financial Results and Provides Business Update May 15, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study April 04, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 31, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division March 21, 2023 From Vivani Medical, Inc. Via Business Wire Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates November 14, 2022 From Vivani Medical, Inc. Via Business Wire Vivani Medical to Present at the ThinkEquity Investor Conference October 17, 2022 From Vivani Medical, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.